Clinical Proof for AI-Discovered Antibody Medicines
Phase 2 VMS success de-risks AbCellera as a platform biotech
A single subcutaneous dose of ABCL635, an NK3-receptor antibody, cut moderate-to-severe vasomotor-symptom frequency by 83% at week 4 versus 33% for placebo, a placebo-adjusted drop of 5.3 events per day (p<0.001), and also improved severity, sleep, and global impression with a favorable tolerability profile. Best-in-class, long-acting, non-hormonal efficacy in a large women's-health market is a platform proof point for AbCellera's antibody engine and supports pipeline value beyond a single asset.
| Instrument | Side | Target | Reason |
|---|---|---|---|
| ABCL | Long | Positive Phase 2 efficacy and tolerability for ABCL635, including an 83% versus 33% reduction in moderate-to-severe hot-flash frequency and a statistically significant placebo-adjusted benefit, show that the antibody platform can produce clinically meaningful, long-acting, non-hormonal medicines. That de-risking supports further upside as Phase 3 and additional pipeline readouts arrive. |
Themes
The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.